Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses

OncoImmunology

Volumn 5, Issue 6, 2016, Pages

  Rekoske, Brian T ^a   Olson, Brian M ^b   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

DNA vaccine; PD 1; PD L1; prostate cancer; prostatic acid phosphatase (PAP)

Indexed keywords

GAMMA INTERFERON; PROGRAMMED DEATH 1 LIGAND 1; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPERSENSITIVITY; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; T LYMPHOCYTE;

EID: 84976528844     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1165377     Document Type: Article

References (42)

1. J.Couzin-Frankel. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432-3; PMID:24357284; 10.1126/science.342.6165.1432
2. Y.Iwai, M.Ishida, Y.Tanaka, T.Okazaki, T.Honjo, N.Minato. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99:12293-7; PMID:12218188; 10.1073/pnas.192461099
3. C.Blank, T.F.Gajewski, A.Mackensen. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother 2005; 54:307-14; PMID:15599732; 10.1007/s00262-004-0593-x
4. J.R.Brahmer, S.S.Tykodi, L.Q.M.Chow, W.-J.Hwu, S.L.Topalian, P.Hwu, C.G.Drake, L.H.Camacho, J.Kauh, K.Odunsi et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; 10.1056/NEJMoa1200694
5. S.L.Topalian, F.S.Hodi, J.R.Brahmer, S.N.Gettinger, D.C.Smith, D.F.McDermott, J.D.Powderly, R.D.Carvajal, J.A.Sosman, M.B.Atkins et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; 10.1056/NEJMoa1200690
6. J.S.Weber, S.O'Day, W.Urba, J.Powderly, G.Nichol, M.Yellin, J.Snively, E.Hersh. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950-6; PMID:19018089; 10.1200/JCO.2008.16.1927
7. T.Powles, J.P.Eder, G.D.Fine, F.S.Braiteh, Y.Loriot, C.Cruz, J.Bellmunt, H.A.Burris, D.P.Petrylak, S.Teng et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; 10.1038/nature13904
8. O.Hamid, C.Robert, A.Daud, F.S.Hodi, W.-J.Hwu, R.Kefford, J.D.Wolchok, P.Hersey, R.W.Joseph, J.S.Weber et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; 10.1056/NEJMoa1305133
9. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, J.Weber, C.Garbe, C.Lebbe, J.-F.Baurain, A.Testori, J.-J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; 10.1056/NEJMoa1104621
10. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; 10.1056/NEJMoa1003466
11. C.Robert, G.V.Long, B.Brady, C.Dutriaux, M.Maio, L.Mortier, J.C.Hassel, P.Rutkowski, C.McNeil, E.Kalinka-Warzocha et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; 10.1056/NEJMoa1412082
12. M.A.Postow, J.Chesney, A.C.Pavlick, C.Robert, K.Grossmann, D.McDermott, G.P.Linette, N.Meyer, J.K.Giguere, S.S.Agarwala et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-17; PMID:25891304; 10.1056/NEJMoa1414428
13. C.Robert, A.Ribas, J.D.Wolchok, F.S.Hodi, O.Hamid, R.Kefford, J.S.Weber, A.M.Joshua, W.-J.Hwu, T.C.Gangadhar et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384:1109-17; PMID:25034862; 10.1016/S0140-6736(14)60958-2
14. R.J.Motzer, B.Escudier, D.F.McDermott, S.George, H.J.Hammers, S.Srinivas, S.S.Tykodi, J.A.Sosman, G.Procopio, E.R.Plimack et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015; 373:1803-13; PMID:26406148; 10.1056/NEJMoa1510665
15. J.R.Brahmer, C.G.Drake, I.Wollner, J.D.Powderly, J.Picus, W.H.Sharfman, E.Stankevich, A.Pons, T.M.Salay, T.L.McMiller et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167-75; PMID:20516446; 10.1200/JCO.2009.26.7609
16. T.N.Schumacher, R.D.Schreiber. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; 10.1126/science.aaa4971
17. N.A.Rizvi, M.D.Hellmann, A.Snyder, P.Kvistborg, V.Makarov, J.J.Havel, W.Lee, J.Yuan, P.Wong, T.S.Ho et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8; PMID:25765070; 10.1126/science.aaa1348
18. D.T.Le, J.N.Uram, H.Wang, B.R.Bartlett, H.Kemberling, A.D.Eyring, A.D.Skora, B.S.Luber, N.S.Azad, D.Laheru et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372:2509-20; PMID:26028255; 10.1056/NEJMoa1500596
19. J.M.Taube, A.Klein, J.R.Brahmer, H.Xu, X.Pan, J.H.Kim, L.Chen, D.M.Pardoll, S.L.Topalian, R.A.Anders. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. Clin Cancer Res 2014; 20:5064-74; PMID:24714771; 10.1158/1078-0432.CCR-13-3271
20. R.S.Herbst, J.-C.Soria, M.Kowanetz, G.D.Fine, O.Hamid, M.S.Gordon, J.A.Sosman, D.F.McDermott, J.D.Powderly, S.N.Gettinger et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515:563-7; PMID:25428504; 10.1038/nature14011
21. M.E.Keir, M.J.Butte, G.J.Freeman, A.H.Sharpe. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26:677-704; PMID:18173375; 10.1146/annurev.immunol.26.021607.090331
22. Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)- tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. (in press) PMID:27059553
23. M.Crittenden, H.Kohrt, R.Levy, J.Jones, K.Camphausen, A.Dicker, S.Demaria, S.Formenti. Current clinical trials testing combinations of immunotherapy and radiation. Semin Radiat Oncol 2015; 25:54-64; PMID:25481267; 10.1016/j.semradonc.2014.07.003
24. C.Tang, X.Wang, H.Soh, S.Seyedin, M.A.Cortez, S.Krishnan, E.Massarelli, D.Hong, A.Naing, A.Diab et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res 2014; 2:831-8; PMID:25187273; 10.1158/2326-6066.CIR-14-0069
25. D.G.McNeel, H.A.Smith, J.C.Eickhoff, J.M.Lang, M.J.Staab, G.Wilding, G.Liu. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother 2012; 61:1137-47; PMID:22210552; 10.1007/s00262-011-1193-1
26. A.J.M.Van den Eertwegh, J.Versluis, H.P.van den Berg, S.J.A.M.Santegoets, R.J.A.van Moorselaar, T.M.van der Sluis, H.E.Gall, T.C.Harding, K.Jooss, I.Lowy et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:509-17; PMID:22326922; 10.1016/S1470-2045(12)70007-4
27. D.T.Le, E.Lutz, J.N.Uram, E.A.Sugar, B.Onners, S.Solt, L.Zheng, L.A.Diaz, R.C.Donehower, E.M.Jaffee et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; 10.1097/CJI.0b013e31829fb7a2
28. B.T.Rekoske, H.A.Smith, B.M.Olson, B.B.Maricque, D.G.McNeel. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization. Cancer Immunol Res 2015; 3:946-55; PMID:26041735; 10.1158/2326-6066.CIR-14-0206
29. J.Fu, I.-J.Malm, D.K.Kadayakkara, H.Levitsky, D.Pardoll, Y.J.Kim. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res 2014; 74:4042-52; PMID:24812273; 10.1158/0008-5472.CAN-13-2685
30. D.G.McNeel, J.T.Becker, J.C.Eickhoff, L.E.Johnson, E.S.Bradley, I.F.Pohlkamp, M.J.Staab, G.Liu, G.Wilding, B.M.Olson. Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase (PAP) in Patients with Castration-Resistant Prostate Cancer. Clin Cancer Res 2014; 20:3692-704; PMID:24850844; 10.1158/1078-0432.CCR-14-0169
31. J.T.Becker, B.M.Olson, L.E.Johnson, J.G.Davies, E.J.Dunphy, D.G.McNeel. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639-47; PMID:20551832; 10.1097/CJI.0b013e3181dda23e
32. J.Laborda. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 1991; 19:3998; PMID:1861990; 10.1093/nar/19.14.3998
33. B.M.Olson, E.Jankowska-Gan, J.T.Becker, D.A.A.Vignali, W.J.Burlingham, D.G.McNeel. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade. J Immunol 2012; 189:5590-601; PMID:23152566; 10.4049/jimmunol.1201744
34. B.M.Olson, T.P.Frye, L.E.Johnson, L.Fong, K.L.Knutson, M.L.Disis, D.G.McNeel. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 2010; 59:943-53; PMID:20140431; 10.1007/s00262-010-0820-6
35. L.Chéry, H.-M.Lam, I.Coleman, B.Lakely, R.Coleman, S.Larson, J.A.Aguirre-Ghiso, J.Xia, R.Gulati, P.S.Nelson et al. Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget 2014; 5:9939-51; PMID:25301725; 10.18632/oncotarget.2480
36. C.Zhu, A.C.Anderson, A.Schubart, H.Xiong, J.Imitola, S.J.Khoury, X.X.Zheng, T.B.Strom, V.K.Kuchroo. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6:1245-52; PMID:16286920; 10.1038/ni1271
37. L.C.Gonzalez, K.M.Loyet, J.Calemine-Fenaux, V.Chauhan, B.Wranik, W.Ouyang, D.L.Eaton. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA 2005; 102:1116-21; PMID:15647361; 10.1073/pnas.0409071102
38. J.R.Sedy, M.Gavrieli, K.G.Potter, M.A.Hurchla, R.C.Lindsley, K.Hildner, S.Scheu, K.Pfeffer, C.F.Ware, T.L.Murphy et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6:90-8; PMID:15568026; 10.1038/ni1144
39. L.Fong, P.Carroll, V.Weinberg, S.Chan, J.Lewis, J.Corman, C.L.Amling, R.A.Stephenson, J.Simko, N.A.Sheikh et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst 2014; 106; PMID:25255802; 10.1093/jnci/dju268
40. M.J.Eppihimer, J.Gunn, G.J.Freeman, E.A.Greenfield, T.Chernova, J.Erickson, J.P.Leonard. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation 2002; 9:133-45; PMID:11932780; 10.1080/713774061
41. J.Galon, A.Costes, F.Sanchez-Cabo, A.Kirilovsky, B.Mlecnik, C.Lagorce-Pagès, M.Tosolini, M.Camus, A.Berger, P.Wind et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; 10.1126/science.1129139
42. D.G.McNeel, T.A.Gardner, C.S.Higano, P.W.Kantoff, E.J.Small, M.H.Wener, R.B.Sims, T.DeVries, N.A.Sheikh, R.Dreicer. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res 2014; 2:988-99; PMID:25189164; 10.1158/2326-6066.CIR-14-0073